Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Kezar Life Sciences (KZR) over the last 5 years, with Q1 2025 value amounting to $8000.0.

  • Kezar Life Sciences' Capital Expenditures changed N/A to $8000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $19000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $29000.0 for FY2024, which is 9839.78% down from last year.
  • Latest data reveals that Kezar Life Sciences reported Capital Expenditures of $8000.0 as of Q1 2025.
  • In the past 5 years, Kezar Life Sciences' Capital Expenditures registered a high of $1.2 million during Q1 2023, and its lowest value of $1000.0 during Q4 2023.
  • For the 5-year period, Kezar Life Sciences' Capital Expenditures averaged around $276214.3, with its median value being $168000.0 (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 9970.85% in 2023, then soared by 100000.0% in 2024.
  • Over the past 5 years, Kezar Life Sciences' Capital Expenditures (Quarter) stood at $264000.0 in 2021, then rose by 29.92% to $343000.0 in 2022, then tumbled by 99.71% to $1000.0 in 2023, then skyrocketed by 1000.0% to $11000.0 in 2024, then decreased by 27.27% to $8000.0 in 2025.
  • Its last three reported values are $8000.0 in Q1 2025, $11000.0 for Q4 2024, and $18000.0 during Q3 2024.